
Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.
Jorge Garcia, MD, FACP, provides insight on the case of a 69-year-old man with mCRPC and assesses the classes of agents currently available as treatment options.
Case:A 69-Year-Old Man with Advanced Castrate Resistant Prostate Cancer
Initial presentation
Clinical Workup
Treatment and Follow-Up






